Infusion of autologous macrophages to treat liver cirrhosis. Notable that, after 1 year, there were no deaths in the experimental arm [n=27] and 3 in the control arm [n=24]. Could this replace liver transplant in the future?

Post-surgical ctDNA MRD status is prognostic in colorectal cancer. I was especially intrigued that adjuvant chemotherapy seemed to have benefit almost entirely in MRD+ patients.

Encouraging results combining cabozantinib with anti-PD1 in HNSCC. Would be great to have a biomarker of efficacy to de-risk phase 3 given LEAP-10 data.

High response rate of anti-PD1 in Kaposi's sarcoma. This should be the new standard of care.

Great demonstration of anti-PD1 crossing blood-brain-barrier and reaching GBM tumors with signficant increase in CD8 and TME changes. Resistance is not a matter of drug not getting to the tumor.

Elegant and effective. Really interesting approach to CAR-T engineering.

Highlighting the temporal and spatial coordination of CD4/CD8/DC interactions.

Mandated Medicaid coverage of the routine costs of clinical trial participation increases participation by 5% in underserved minorities. Why is this not universal across the country?

This is remarkable work from the Surgery Branch - proof or principle that autologous T cells can be transduced with personalized neoantigen TCRs that produce clinical responses in patients with refractory colorectal cancer.

Remarkable work cataloguing the diversity and complexity of tumor associated macrophages. This will be a valuable tool in cancer immunotherapy.

Great study linking emotional distress to immunotherapy treatment outcomes. The effect size is similar to PDL1 status. Measures of psychological well-being should be part of every oncology assessment.

This is what happens when one combines a biomarker defined patient population with effectively directed systemic therapy - median follow-up 26 months, no recurrences.

Inflammatory tongue conditions appear to predispose to oral tongue cancer. Etiology remains unclear but beginning to understand why this disease is rising in incidence.

@harpreet_md @oncodaily Congratulations.

Hindsight is easy but PDL1 expression appears to strongly predict pCR. That should help pave the path forward.

We need to change the paradigm in LA-HNSCC. Adding anti-PD1/PDL1 concurrently or adjuvantly has not worked. I think the solution will come with better biomarkers, changing radiation dosing, and rationally applied therapy sequencing.

Intriguing mechansim underscoring the influence of cancer associated fibroblasts in treatment resistence. These cells are not just bystanders.

@Dr_RShatsky @UCSDCancer Be bold, wear it.

Targeting antigens with TCR-T and vaccine simultaneously offers a potential strategy to enhance efficacy of both.

Impressive clinical responses to CD19 CAR-T in patients with autoimmune disease. 'Immunosuppressive therapy was completely stopped in all the patients.'